Breaking news

Nvidia-Backed CoreWeave Eyes $35 Billion IPO Amid AI Boom

CoreWeave, a cloud computing company specializing in AI infrastructure, is preparing for a major IPO on Nasdaq under the ticker “CRWV.” The Nvidia-backed firm aims to raise up to $2.7 billion, setting a valuation exceeding $35 billion, making it one of the biggest tech listings in recent years.

Key Facts

  • 49 million shares priced between $47 and $55 each.
  • Revenue skyrocketed from $229M in 2023 to $1.9B in 2024, though net losses also climbed to $863M.
  • IPO led by Morgan Stanley, JP Morgan, and Goldman Sachs.
  • $11.9B deal with OpenAI, including a $350M private investment from OpenAI.
  • AI infrastructure powered by 300,000 Nvidia GPUs, supporting Meta, IBM, and Microsoft.

The Nvidia Partnership

Nvidia’s strategic backing has been crucial in CoreWeave’s rise. The firm secured $2.3B in debt financing using Nvidia GPUs as collateral and is integrating Nvidia’s latest GB200 NVL72 cloud instances, offering cutting-edge AI processing capabilities.

Market Impact

CoreWeave’s IPO could revive the tech IPO market and signal a strong investor appetite for AI-driven companies. However, economic uncertainty and shifts in AI infrastructure strategies—especially from major clients like Microsoft—add complexity to the landscape.As the AI boom continues, CoreWeave is positioning itself as a key player in next-gen cloud computing, directly competing with Amazon and Google.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

The Future Forbes Realty Global Properties
Uol
Aretilaw firm
eCredo

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter